Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SeaStar Medical Holding (ICUCW) EBIT (2023 - 2025)

SeaStar Medical Holding's EBIT history spans 3 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, EBIT rose 238.62% year-over-year to $6.6 million; the TTM value through Dec 2025 reached -$2.5 million, up 85.71%, while the annual FY2025 figure was -$2.6 million, 85.7% up from the prior year.
  • EBIT reached $6.6 million in Q4 2025 per ICUCW's latest filing, up from -$3.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $6.6 million in Q4 2025 to a low of -$4.8 million in Q4 2024.
  • Average EBIT over 3 years is -$2.9 million, with a median of -$3.8 million recorded in 2023.
  • Peak YoY movement for EBIT: plummeted 62.31% in 2024, then soared 238.62% in 2025.
  • A 3-year view of EBIT shows it stood at -$2.9 million in 2023, then tumbled by 62.31% to -$4.8 million in 2024, then skyrocketed by 238.62% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for ICUCW's EBIT are $6.6 million (Q4 2025), -$3.6 million (Q3 2025), and -$1.8 million (Q2 2025).